{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:11:32Z","timestamp":1792120292891,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 di Catania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pcad.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:09:31Z","timestamp":1748286571000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience"],"prefix":"10.1016","volume":"92","author":[{"given":"Giosiana","family":"Bosco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Scilletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Esposto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Prezzavento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernestina Marianna","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Malaguarnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.05.008_bb0005","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.05.008_bb0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.05.008_bb0015","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11883-024-01225-3","article-title":"Cardiovascular risk estimation and stratification among individuals with hypercholesterolemia","volume":"26","author":"Bosco","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.pcad.2025.05.008_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0025","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.05.008_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2016.07.009","article-title":"Statin intolerance: a literature review and management strategies","volume":"59","author":"Saxon","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"The Lancet"},{"key":"10.1016\/j.pcad.2025.05.008_bb0040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pcad.2019.10.003","article-title":"Reducing cardiovascular risk in patients with familial hypercholesterolemia: risk prediction and lipid management","volume":"62","author":"Miname","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.05.008_bb0050","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.05.008_bb0055","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/jcm12062444","article-title":"Management of Statin Intolerant Patients in the era of novel lipid lowering therapies: a critical approach in clinical practice","volume":"12","author":"Bosco","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0065","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2025.05.008_bb0070","unstructured":"ClinicalTrials.gov. NCT03705234. A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03705234 (11 March 2025, date last accessed). n.d."},{"key":"10.1016\/j.pcad.2025.05.008_bb0075","unstructured":"ClinicalTrials.gov. NCT05030428. Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05030428 (11 March 2025, date last accessed). n.d."},{"key":"10.1016\/j.pcad.2025.05.008_bb0080","unstructured":"ClinicalTrials.gov. NCT05739383. A Study of Inclisiran to Prevent Cardiovascular Events in High-Risk Primary Prevention Patients. https:\/\/clinicaltrials.gov\/study\/NCT05739383(11 March 2025, date last accessed). n.d."},{"key":"10.1016\/j.pcad.2025.05.008_bb0085","first-page":"25","article-title":"Pulse wave velocity: methodology, clinical applications, and interplay with heart rate variability","author":"Pilz","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.numecd.2017.07.003","article-title":"Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile","volume":"28","author":"Scicali","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2018.08.013","article-title":"Evaluation of the performance of Dutch lipid clinic network score in an Italian FH population: the LIPIGEN study","volume":"277","author":"Casula","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-025-02683-y","article-title":"Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation","volume":"24","author":"Di Giacomo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/918368","article-title":"Adult current smoking: differences in definitions and prevalence estimates\u2014NHIS and NSDUH, 2008","volume":"2012","author":"Ryan","year":"2012","journal-title":"J Environ Public Health"},{"key":"10.1016\/j.pcad.2025.05.008_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2024.12.002","article-title":"Evaluations of metabolic and innate immunity profiles in subjects with familial hypercholesterolemia with or without subclinical atherosclerosis","volume":"132","author":"Bosco","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pcad.2023.02.007","article-title":"PCSK9 inhibitor, ezetimibe, and bempedoic acid: evidence-based therapies for statin-intolerant patients","volume":"79","author":"Gunta","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0120","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/cells8080910","article-title":"1 h Postload glycemia is associated with low endogenous secretory receptor for advanced glycation end product levels and early markers of cardiovascular disease","volume":"8","author":"Di Pino","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.05.008_bb0125","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/00365521.2014.985707","article-title":"Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency","volume":"50","author":"Spadaro","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0135","first-page":"15","article-title":"The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia","author":"Bosco","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pcad.2025.05.008_bb0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pcad.2020.04.004","article-title":"What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?","volume":"63","author":"Cybulska","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0145","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/liv.16005","article-title":"Acute hyperbilirubinemia determines an early subclinical renal damage: evaluation of tubular biomarkers in cholemic nephropathy","volume":"44","author":"Scilletta","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.pcad.2025.05.008_bb0150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00592-021-01703-z","article-title":"Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting","volume":"58","author":"Scicali","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","article-title":"Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity","volume":"30","author":"Van Bortel","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2025.05.008_bb0160","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of Inclisiran","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","article-title":"First clinical experiences with inclisiran in a real-world setting","volume":"17","author":"Mulder","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0175","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2025.05.008_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9\u2014impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.pcad.2025.05.008_bb0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40256-024-00702-z","article-title":"A Meta-analysis of the regulation of low-density lipoprotein cholesterol and proprotein convertase subtilisin-Kexin type 9 with Inclisiran","volume":"25","author":"Li","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pcad.2025.05.008_bb0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12944-024-02294-8","article-title":"Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999\u20132018 study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.05.003","article-title":"Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service","volume":"18","author":"Naoum","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0200","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of Inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.pcad.2025.05.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117354","article-title":"Inclisiran in patients with prior myocardial infarction: a post hoc pooled analysis of the ORION-10 and ORION-11 phase 3 randomised trials","volume":"386","author":"Landmesser","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0215","first-page":"6","article-title":"Pulse wave velocity in atherosclerosis","author":"Kim","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.05.008_bb0220","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2015.05.031","article-title":"Brachial-ankle pulse wave velocity is associated with coronary calcium in young and middle-aged asymptomatic adults: the Kangbuk Samsung health study","volume":"241","author":"Cainzos-Achirica","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0225","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.atherosclerosis.2011.09.013","article-title":"The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke","volume":"219","author":"Kim","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2025.05.008_bb0230","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5551\/jat.33084","article-title":"Brachial-ankle pulse wave velocity is associated with composite carotid and coronary atherosclerosis in a middle-aged asymptomatic population","volume":"23","author":"Joo","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.pcad.2025.05.008_bb0235","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardiores.2005.01.012","article-title":"Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension","volume":"66","author":"Dao","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2025.05.008_bb0240","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","article-title":"Mechanisms, pathophysiology, and therapy of arterial stiffness","volume":"25","author":"Zieman","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0245","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","article-title":"Prediction of cardiovascular events and all-cause mortality with arterial stiffness","volume":"55","author":"Vlachopoulos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0250","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2362.2010.02260.x","article-title":"Pulse wave velocity and augmentation index, but not intima-media thickness, are early indicators of vascular damage in hypercholesterolemic children","volume":"40","author":"Riggio","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pcad.2025.05.008_bb0255","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2017.12.051","article-title":"Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia","volume":"255","author":"Canepa","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2020.01.015","article-title":"Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a two\u2013lipid center real-world experience","volume":"14","author":"Mandraffino","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2025.05.008_bb0265","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/biom12040562","article-title":"PCSK9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease: results of six-month add-on PCSK9 inhibitor therapy","volume":"12","author":"Toscano","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.pcad.2025.05.008_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of Inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9\u2014a narrative review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.pcad.2025.05.008_bb0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11883-024-01271-x","article-title":"Inclisiran, reasons for a novel agent in a crowded therapeutic field","volume":"27","author":"Di Giacomo-Barbagallo","year":"2024","journal-title":"Curr Atheroscler Rep"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:08:51Z","timestamp":1763183331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":55,"alternative-id":["S0033062025000787"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.05.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}